Comparison of the Efficacy of Romosozumab and Teriparatide for the Management of Osteoporotic Vertebral Compression Fractures.

Autor: Park D; Department of Neurological Surgery, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.; College of Nursing, Korea University, Seoul, Korea., Kim SE; Department of Neurological Surgery, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea., Shin HK; Department of Neurological Surgery, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea., Seo J; Department of Neurosurgery, Spine Center, The Leon Wiltse Memorial Hospital, Suwon, Korea., Joo JK; Department of Neurosurgery, St. Mary Central Madichuk Clinic, Goyang, Korea., Kim C; Department of Industrial and Management Engineering, Myongji University, Seoul, Korea., Lee SH; Department of Neurosurgery, Gyeongsang National University Hospital, Gyeongsang National University School of Medicine, Jinju, Korea., Park JH; Department of Neurological Surgery, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
Jazyk: angličtina
Zdroj: Neurospine [Neurospine] 2023 Dec; Vol. 20 (4), pp. 1217-1223. Date of Electronic Publication: 2023 Dec 31.
DOI: 10.14245/ns.2347030.515
Abstrakt: Objective: Romosozumab is increasingly employed to manage osteoporosis. However, no studies have analyzed its effects on recent osteoporotic vertebral compression fractures (OVCFs). Therefore, this study aimed to evaluate the efficacy of romosozumab compared with teriparatide in managing OVCFs.
Methods: The electronic medical records of postmenopausal patients with recent OVCFs who were administered romosozumab or teriparatide for one year from March 2018 to August 2022 were retrospectively reviewed. We compared the 2 groups for demographics, radiological outcomes (compression ratio, Cobb angle, and bone mineral density [BMD]), and clinical outcomes (Numerical Rating Scale [NRS] for back pain).
Results: Fifty-five patients with OVCFs, 32 patients treated with romosozumab and 23 with teriparatide, were included in this study. The change of BMD (g/cm2) values was significantly higher (p = 0.016) in the romosozumab (0.04 ± 0.06) than in the teriparatide group (0.00 ± 0.08) in the femur total. Furthermore, in subgroup analysis, the change of BMD (g/cm2) values in the lumbar spine was significantly higher (p = 0.016) in the romosozumab (0.12 ± 0.06) than in the teriparatide group (0.07 ± 0.06) in the lumbar spine. The decrease in NRS was significantly higher (p = 0.013) in the romosozumab (6.6 ± 2.0) than in the teriparatide group (5.5 ± 2.1). However, there was no significant difference in radiologic outcomes between the 2 groups.
Conclusion: Our findings suggest that romosozumab may be more effective than teriparatide in treating OVCFs in postmenopausal females, particularly in improving BMD and reducing back pain as measured by NRS.
Databáze: MEDLINE
Externí odkaz: